EICHOR
● Active Not Recruiting
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Condition: Advanced Solid Neoplasms · Sponsor: Merck Sharp & Dohme LLC
About this study
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (130)
| The University of Arizona Cancer Center - North Campus ( Site 0011) | Tucson, Arizona, United States | — |
| St Joseph Heritage Healthcare-Oncology ( Site 0056) | Fullerton, California, United States | — |
| Cedars Sinai Medical Center ( Site 0002) | Los Angeles, California, United States | — |
| UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007) | San Francisco, California, United States | — |
| Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092) | Aurora, Colorado, United States | — |
| Winship Cancer Institute of Emory University ( Site 0025) | Atlanta, Georgia, United States | — |
| Augusta University ( Site 0028) | Augusta, Georgia, United States | — |
| Markey Cancer Center ( Site 0018) | Lexington, Kentucky, United States | — |
| University of Maryland ( Site 0050) | Baltimore, Maryland, United States | — |
| Weinberg Cancer Institute at Franklin Square ( Site 0054) | Baltimore, Maryland, United States | — |
| University of Massachusetts ( Site 0017) | Worcester, Massachusetts, United States | — |
| Henry Ford Health System ( Site 0060) | Detroit, Michigan, United States | — |
+ 118 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03742895